Intrexon Corp (NYSE:XON) shares shot up 5.9% on Friday . The stock traded as high as $16.92 and last traded at $16.75. 2,420,117 shares changed hands during trading, an increase of 18% from the average session volume of 2,053,428 shares. The stock had previously closed at $15.82.
Several brokerages have recently weighed in on XON. JPMorgan Chase & Co. restated a “neutral” rating and set a $18.00 target price (down from $22.00) on shares of Intrexon in a report on Monday, March 5th. Bank of America lowered their target price on Intrexon from $21.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, March 2nd. Northland Securities restated a “buy” rating and set a $17.00 target price on shares of Intrexon in a report on Friday, March 2nd. ValuEngine cut Intrexon from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research upgraded Intrexon from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $34.71.
The company has a current ratio of 1.92, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01.
Intrexon (NYSE:XON) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.08. The firm had revenue of $77.03 million for the quarter, compared to analyst estimates of $48.16 million. Intrexon had a negative net margin of 50.61% and a negative return on equity of 16.94%. The business’s revenue for the quarter was up 67.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.37) EPS. research analysts expect that Intrexon Corp will post -0.87 earnings per share for the current year.
In other news, CEO Randal J. Kirk purchased 1,000,000 shares of Intrexon stock in a transaction dated Friday, January 19th. The shares were purchased at an average price of $12.50 per share, with a total value of $12,500,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 55.10% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Xact Kapitalforvaltning AB purchased a new stake in Intrexon in the fourth quarter valued at approximately $138,000. Dixon Hubard Feinour & Brown Inc. VA raised its position in Intrexon by 23.6% in the fourth quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 85,944 shares of the biotechnology company’s stock valued at $990,000 after purchasing an additional 16,393 shares during the period. Macquarie Group Ltd. raised its position in Intrexon by 11.8% in the fourth quarter. Macquarie Group Ltd. now owns 40,231 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 4,236 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its position in Intrexon by 56.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 42,035 shares of the biotechnology company’s stock valued at $484,000 after purchasing an additional 15,090 shares during the period. Finally, Teachers Advisors LLC raised its position in Intrexon by 9.0% in the fourth quarter. Teachers Advisors LLC now owns 68,326 shares of the biotechnology company’s stock valued at $787,000 after purchasing an additional 5,623 shares during the period. 76.84% of the stock is currently owned by institutional investors.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.